Allopregnanolone and mood disorders

@article{Bckstrm2014AllopregnanoloneAM,
  title={Allopregnanolone and mood disorders},
  author={Torbj{\"o}rn B{\"a}ckstr{\"o}m and Marie Bixo and Maja Johansson and Sigrid Nyberg and Lindsey Ossewaarde and Gianna Ragagnin and Ivanka Savic and Jessica Str{\"o}mberg and Erika Timby and Frank van Broekhoven and Guido A. van Wingen},
  journal={Progress in Neurobiology},
  year={2014},
  volume={113},
  pages={88-94}
}

Figures from this paper

GABAA Receptor-Modulating Steroids in Relation to Women’s Behavioral Health
TLDR
In certain women, increased negative mood relates to the progesterone metabolite, allopregnanolone (allo), during the luteal phase of ovulatory menstrual cycles, the premenstrual dysphoric disorder (PMDD), and this effect can be induced by all GABAA receptor modulators in low concentrations whereas higher concentrations are calming.
Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder
TLDR
The underlying studies of this review provide evidence that allopregnanolone is the provoking factor behind the negative mood symptoms in PMDD and that isoallopreg nanolone could ameliorate the symptoms as a result of its ability to antagonise the allopreginolone effect on the GABAA receptor.
Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls—a pilot study
TLDR
The effect of exogenous allopregnanolone is associated with menstrual cycle phase in PMDD patients and in controls, and the results suggest an altered sensitivity to allopreginolone in PM DD patients.
Polycystic Ovary Syndrome, Affective Symptoms, and Neuroactive Steroids: a Focus on Allopregnanolone
TLDR
Prospective studies evaluating associations between psychiatric symptoms and NAS are needed to elucidate the biological causes of the increased rates of psychiatric symptoms among women with PCOS and inform clinical treatment, and allopregnanolone, with its role in normal reproductive function, menstrual dysregulation, makes it a particularly intriguing candidate for future investigation.
Response to sertraline is associated with reduction in anxiety-potentiated startle in premenstrual dysphoric disorder.
TLDR
Altered alterations in APS suggest potential GABA-A-R changes across the menstrual cycle and in response to sertraline among treatment responders, suggesting impaired ability to modulate arousal reactivity.
Allopregnanolone and reproductive psychiatry: an overview
TLDR
An overview of the relationship between allopregnanolone and mood at menarche, in the menstrual cycle; in the peripartum; and in the menopausal transition finds ALLO dysregulation is identified in all of these transitions and found to be associated with mood symptoms.
The role of ovarian hormone-derived neurosteroids on the regulation of GABAA receptors in affective disorders
TLDR
GABAAR plasticity associated with alterations in neurosteroid levels represents a homeostatic compensatory mechanism to maintain an ideal level of inhibition to offset the potentiating effects of neurosteroids on GABAergic inhibition.
Hormonal Contraception and Depression: Updated Evidence and Implications in Clinical Practice
TLDR
An update of the literature on the possible appearance of depressive symptoms when using hormonal contraceptives is provided, and the possible explanations of this problem are investigated based on animal and human studies.
Progesterone, reproduction, and psychiatric illness.
...
...

References

SHOWING 1-10 OF 94 REFERENCES
The Role of Hormones and Hormonal Treatments in Premenstrual Syndrome
TLDR
SSRIs and substances inhibiting ovulation, such as gonadotrophin-releasing hormone (GnRH) agonists, have proven to be effective treatments and add-back hormone replacement therapy is recommended to avoid adverse effects when high dosages of GnRH agonists are sed.
Allopregnanolone concentration and mood—a bimodal association in postmenopausal women treated with oral progesterone
TLDR
Mood effects during progesterone treatment seem to be related to allopregnanolone concentration, and a bimodal association between allopreginolone and adverse mood is evident.
Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: A pilot study
Progesterone selectively increases amygdala reactivity in women
TLDR
Investigating whether a single progesterone administration to healthy young women in their follicular phase modulates the amygdala response to salient, biologically relevant stimuli reveals a neural mechanism by which progester one may mediate adverse effects on anxiety and mood.
Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome
TLDR
Treatment response, whether induced by buserelin or placebo, appears to be associated with a decrease in allopregnanolone concentration, which was associated with improvement in symptoms compared with pre-treatment ratings.
Pharmacokinetic and behavioral effects of allopregnanolone in healthy women
TLDR
The behavioral effects of allopregnanolone are similar to that of its 5β-stereoisomer, pregnanolone, and decreases saccadic eye movement parameters and increases subjective ratings of sedation that correlate with increased serum concentrations of this neuroactive steroid.
Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.
TLDR
In women with premenstrual syndrome, the occurrence of symptoms represents an abnormal response to normal hormonal changes.
GABAA receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid
TLDR
In this model, withdrawal of progesterone leads to increased seizure susceptibility and insensitivity to benzodiazepine sedatives through an effect on gene transcription, which is due to reduced levels of 3α,5α-THP which enhance transcription of the α4 subunit of the GABAA receptor.
Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences.
TLDR
It is demonstrated that although men show an age-related decrease, serum allopregnanolone levels in women do not change with age and correlate with P levels during the menstrual cycle and in response to endocrine tests.
...
...